Clinical Trial

A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to find out whether Tec-RVd (teclistamab, lenalidomide, bortezomib, and dexamethasone) after 3 treatment Cycles of Dara-RVd (daratumumab, lenalidomide, bortezomib, and dexamethasone) is a safe treatment for people with newly diagnosed multiple myeloma (MM).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-25; most recent amendment 2026-02-09.
Trial Details
NCT Number NCT07099391
Lead Sponsor Memorial Sloan Kettering Cancer Center
Conditions Multiple Myeloma
Enrollment 65 participants
Start Date 2025-07-24
Primary Completion 2029-07-24 (estimated)
Study Completion 2029-07-24 (estimated)
Updated on ClinicalTrials.gov 2026-07-28